載入...
Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
Randomized controlled clinical trials and real-life observations indicate that less than 50% of patients with Crohn’s disease (CD) or ulcerative colitis (UC) respond to vedolizumab, a humanized monoclonal antibody that blocks the α4β7 integrin. Since α4β7-expressing lymphocytes mainly infiltrate the...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI AG
2020-02-01
|
| 叢編: | Journal of Clinical Medicine |
| 主題: | |
| 在線閱讀: | https://www.mdpi.com/2077-0383/9/2/385 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|